Evolva’s technologies are based on yeast
Evolva is based on yeast. Humanity has been using yeast for thousands of years and every day, all over the world, yeast is used to make products such as bread, beer and wine. Yeast is part of our daily diet.
Yeast’s importance has led to it being one of the most well studied organisms in the world, which in turn has allowed yeast to become important in the production of certain pharmaceuticals, vaccines and other important products.
Evolva’s approach bridges the modern and traditional uses of yeast. On the modern side, we create yeasts with the ability to make ingredients more normally found elsewhere in nature. On the traditional side, our production methods would be recognisable to any brewer. We are brewers for the 21st century.
Over the past ten years, Evolva has invested over CHF 170 million in research and development, half of it funded by external partners. The acquisition of Allylix in December 2014 significantly expanded our reach in molecular biology, analytical chemistry, manufacturing and application development.
As of year-end 2014, we employed 116 people in R&D, scale-up and production management. We operate some 4,500 square metres of state-of-the-art laboratories. We own or have exclusive licences to some 500 patents or patent applications across 90 different families. About 220 of these patents are currently granted. These patents protect our technologies, pathways and products.
Explain more about the Technical Implementation.